$IFF · INTERNATIONAL FLAVORS & FRAGRANCES INC
IFF reported Q3 2026 results with net sales of $1.94B (+4% YoY) and adjusted EPS of $0.83. GAAP results included a $(134)M pre-tax loss from continuing operations, driven by a $236M loss on assets classified as held for sale related to the Food Ingredients divestiture. The company raised the low end of FY2026 guidance for both sales ($7.5B–$7.6B) and adjusted operating EBITDA ($1.55B–$1.60B), and completed its $500M share repurchase program.
- Q3 net sales $1.94B, +4% reported / +5% currency-neutral, with all three segments growing
- GAAP loss from continuing operations before taxes was $(134)M, dragged by a $236M loss on assets classified as held for sale
- Adjusted operating EBITDA $403M (20.8% margin), +6% currency-neutral comparable growth
- FY2026 sales guidance low end raised to $7.5B (from $7.4B); adjusted EBITDA low end raised to $1.55B (from $1.53B)
- Recently completed $500M accelerated share repurchase; Food Ingredients divestiture on track to close by end of Q2 2027
Extended-hours trading shows IFF down 3.45% to $89.00 vs the $92.18 regular close. The GAAP loss and $236M held-for-sale impairment appear to be weighing on sentiment despite the adjusted beat and guidance raise.
The GAAP loss from a $236M impairment charge clashes with an otherwise solid operational quarter and guidance raise, creating a messy signal for investors.
IFF's mid-single-digit volume-driven growth across Taste, Scent, and Health & Biosciences contrasts with peers facing demand softness in specialty ingredients. The Food Ingredients separation remains the key structural catalyst.
Q4 profitability expected to be softer, particularly in Health & Biosciences, due to higher costs and reinvestments. Macroeconomic conditions flagged as a headwind. Total debt to trailing-twelve-months net income at 34.5x is elevated.